Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regulus (RGLS)
NASDAQ:RGLS
Holding RGLS?
Track your performance easily
RGLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.16 - $3.79
Previous CloseN/A
Volume87.19K
Average Volume (3M)315.17K
Market Cap
$81.22M
Enterprise Value$16.66M
Total Cash (Recent Filing)$76.11M
Total Debt (Recent Filing)$19.80M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 20, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding65,500,140
10 Day Avg. Volume361,717
30 Day Avg. Volume315,172
Standard Deviation0.28
R-Squared0.09
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$13.25Price Target Upside1225.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Regulus News
PremiumCompany Announcements
Regulus Therapeutics Reports Q3 2024 Financial Results
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
Bulls Say, Bears Say
Bulls Say
Clinical ResultsFarabursen demonstrated continued target engagement via reductions in polycystin-1/PC1 and polycystin-2/PC2, showing mechanistic dose response.
Financial PositionThe company ended with $87.3M in cash, cash equivalents, and investments, expected to provide runway into 1H26.
Regulatory ProgressRegulus disclosed positive interim data from Cohort 4 with farabursen (RGLS8429) in ADPKD and provided a regulatory update, reaching alignment on key components of a single pivotal study for Accelerated Approval.
Bears Say
Clinical DataThe data have not fully resonated with the Street at this juncture, potentially given the limited sample size.
Financial PerformanceNet loss was $14.1M, or ($0.21) per share, higher than estimated loss of $12.5M.
Product UtilizationTolvaptan is underutilized due to intolerable side effects and high treatment burden.
---
Ownership Overview
2.78% Insiders
11.73% Mutual Funds
39.13% Other Institutional Investors
36.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RGLS FAQ
What was Regulus’s price range in the past 12 months?
Regulus lowest stock price was $1.16 and its highest was $3.79 in the past 12 months.
What is Regulus’s market cap?
Regulus’s market cap is $81.22M.
When is Regulus’s upcoming earnings report date?
Regulus’s upcoming earnings report date is Mar 20, 2025 which is in 47 days.
How were Regulus’s earnings last quarter?
Regulus released its earnings results on Nov 07, 2024. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.169 by -$0.041.
Is Regulus overvalued?
According to Wall Street analysts Regulus’s price is currently Undervalued.
Does Regulus pay dividends?
Regulus does not currently pay dividends.
What is Regulus’s EPS estimate?
Regulus’s EPS estimate is -0.21.
How many shares outstanding does Regulus have?
Regulus has 65,500,140 shares outstanding.
What happened to Regulus’s price movement after its last earnings report?
Regulus reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.169. Following the earnings report the stock price went down -0.676%.
Which hedge fund is a major shareholder of Regulus?
Currently, no hedge funds are holding shares in RGLS
---
Regulus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.25 (1225.00% Upside)
$13.25 (1225.00% Upside)
Blogger Sentiment
Bullish
RGLS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 5.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $74.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.80%
12-Months-Change
Fundamentals
Return on Equity
-72.36%
Trailing 12-Months
Asset Growth
148.40%
Trailing 12-Months
Company Description
Regulus
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
---
RGLS Stock 12 Month Forecast
Average Price Target
$13.25
▲(1225.00% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Moderna
―
Best Analysts Covering RGLS
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
-8.03%
reiterated a buy rating 3 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -8.03% per trade.
---